Monitoring Guidelines for Stage 2 Follicular Lymphoma in Remission After ISRT

Clinical Monitoring Schedule

The American College of Oncology recommends history and physical examination every 3 months for 2 years, every 6 months for three additional years, and then annually with special attention to transformation and secondary malignancies in patients with stage 2 follicular lymphoma in remission after ISRT 1, 2, 3
History and physical examination should be performed every 3 months for the first 2 years, with a focus on detecting transformation and secondary malignancies, including secondary leukemia, in patients with stage 2 follicular lymphoma in remission after ISRT 1, 4
The examination schedule should be every 6 months for years 3-5, and annually thereafter, with ongoing attention to signs of transformation and secondary malignancies in patients with stage 2 follicular lymphoma in remission after ISRT 2, 5
Laboratory monitoring, including complete blood count and LDH, should be performed at 3, 6, 12, and 24 months post-treatment, with laboratory tests only as needed for evaluation of suspicious symptoms after 24 months in patients with stage 2 follicular lymphoma in remission after ISRT 1, 3
Evaluation of thyroid function should be performed at 1, 2, and 5 years if the neck was irradiated, due to the risk of radiation-related thyroid dysfunction in patients with stage 2 follicular lymphoma in remission after ISRT 1, 2

Minimal adequate radiological or ultrasound examinations should be performed at 6, 12, and 24 months after the end of treatment, with imaging studies limited to every 6 months for 2 years, then annually if clinically indicated after local RT in patients with stage 2 follicular lymphoma in remission after ISRT 1, 3, 6

After rituximab therapy, immunoglobulin levels should be monitored periodically, as hypogammaglobulinemia may develop, according to the American College of Oncology guidelines 7
For patients who received rituximab, monitoring for hepatitis B reactivation should be performed for up to 2 years after exposure if the patient has positive hepatitis B serology, due to the risk of hepatitis B reactivation in patients with stage 2 follicular lymphoma in remission after ISRT 6, 8

Inadequate surveillance may result in delayed detection of relapse or transformation, highlighting the importance of regular follow-up in patients with stage 2 follicular lymphoma in remission after ISRT 2, 4
Over-reliance on imaging should be avoided, as clinical examination remains crucial for detecting relapses that may not be visible on imaging, according to the American College of Oncology guidelines 1, 3
Biopsy should be considered for any suspicious new or rapidly growing lesion to rule out transformation to aggressive lymphoma, due to the risk of transformation in patients with stage 2 follicular lymphoma in remission after ISRT 6
Long-term monitoring for radiation-related complications, particularly thyroid dysfunction in patients who received neck irradiation, is essential for patients with stage 2 follicular lymphoma in remission after ISRT 1, 2